GlobalData on MSN8h
AnaptysBio’s atopic dermatitis trial of BTLA agonist misses endpointsAnaptysBio has reported that the ARISE-AD trial of its investigational B and T lymphocyte attenuator (BTLA) agonist, ANB032, ...
AnaptysBio is dropping its atopic dermatitis (AD) drug candidate after the compound failed to reduce eczema area and itch ...
H.C. Wainwright downgraded AnaptysBio (ANAB) to Neutral from Buy with a price target of $19, down from $52, after the company announced topline ...
AnaptysBio, Inc. (NASDAQ:ANAB) announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary ...
Derek Archila, an analyst from Wells Fargo, assigned the Buy rating on AnaptysBio (ANAB – Research Report). The associated price target is ...
Zacks.com on MSN4h
AnaptysBio Stock Down as Eczema Study Fails to Meet GoalsPhase IIb study on ANAB's ANB032 for atopic dermatitis fails to meet goals. The company decides to discontinue any further investment in the candidate.
San Diego, USA-based biotech AnaptysBio today announced that investigational ANB032, a BTLA agonist, did not meet the primary ...
AnaptysBio will end the development of its experimental drug to treat eczema as the treatment failed to meet the goals of a ...
The clinical-stage biotechnology company said its investigational drug ANB032 didn't meet either primary or secondary endpoints in its 201-patient Arise-AD trial as a therapy for atopic dermatitis, ...
Stocktwits on MSN5h
AnaptysBio Stock Under Pressure After Scrapping Eczema Drug Program: Retail Is DevastatedShares of AnaptysBio Inc. remained flat in premarket trading Thursday after plunging over 32% in the prior session, marking ...
Dupilumab treatment improves signs and symptoms of atopic dermatitis (AD) in young children, according to a study p ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback